ALSYMPCA Trial: Updated Analysis of Survival With Radium-223 Treatment in Metastatic Prostate CancerMatthew Stenger
摘要: 770PREASONS FOR PATIENTS (PTS) DISCONTINUING STUDY TREATMENT (TX) IN THE PHASE 3 ALSYMPCA TRIAL OF RADIUM-223 DICHLORIDE (RA-223) IN CASTRATION-RESISTANT PROSTATE CANCER (CRPC) WITH BONE METASTASES (METS)DOI: 10.1093/annonc/mdu336.18 被引量: 1 ...
A randomized, controlled trial of education and physical training for patients with fibromyalgia To determine the effectiveness of self-management education and physical training in decreasing fibromyalgia (FMS) symptoms and increasing physical and psy... CS Burckhardt,K Mannerkorpi,L Hedenberg,.....
O'Sullivan J, Widmark DCJ, Syndikus I, James N, Dall'Oglio M, et al. Hematologic safety of radium‑223 dichloride (Ra‑223) in the phase 3 ALSYMPCA trial in castration‑resistant prostate cancer (CRPC) patients with bone metastases: baseline ...
PO-0737: Effects of Radium-223 Dichloride on Health-Related QOL in CRPC Pts with Bone Mets from the Ph 3 ALSYMPCA Trialannealingcobaltferromagnetic materialsmagnetic domainsmagnetic particlesmagnetisationnanostructured materialsnickelparticle size20 C...
Radium-223 Chloride Safety and Use of External Beam Radiation Therapy (EBRT) in the Phase III Randomized Trial (ALSYMPCA) in Patients With Castration-resistant Prostate Cancer (CRPC) and Bone MetastasesPurpose/Objective(s) Radium-223 chloride (Ra-223), a targeted alpha-emitter, is a calcium ...
EBRT Use and Safety with Radium-223 in Patients with CRPC and Symptomatic Bone Metastases from the ALSYMPCA Trial Professor Sartor presents results from the ALSYMPCA trial which showed radium-223 significantly reduced the risk of EBRT use for bone pain while significant...
Vogelzang NJ, Coleman RE, Michalski JM, Nilsson S, O'Sullivan JM, Parker C, et al. Hematologic safety of radium-223 dichloride: baseline prognostic factors associated with myelosuppression in the ALSYMPCA Trial. Clin Genitourin Cancer 2017; 15:42.e8-52.e8....
Methods Using data from the phase 3 Alpharadin in Symptomatic Prostate Cancer Patients trial, this study estimated important change scores on the FACT-P and the NFPSI-17 via a combination of distribution- and anchor-based methods. These data were also used to establish evidence for the validity...